Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.
نویسندگان
چکیده
Currently used non-specific immunosuppressive drugs often require intervention in myasthenia gravis (MG) and clinical improvement varies widely. To analyze the therapeutic effect of mycophenolate mofetil (MMF) in experimental autoimmune MG (EAMG), rats were immunized with acetylcholine receptors (AChRs) and subsequently treated with MMF or vehicle. MMF treatment resulted in a significant suppression of anti-rat AChR antibody titers. Interestingly, no abnormalities of neuromuscular transmission and adverse side effects were detected in MMF-treated EAMG animals. Moreover, anti-rat AChR antibody titers correlated to an improvement of clinical outcome. In conclusion, our data suggest that MMF acts as a potent immunosuppressant drug in EAMG.
منابع مشابه
Current and emerging treatments for the management of myasthenia gravis
Myasthenia gravis is an autoimmune neuromuscular disorder. There are several treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulation (intraven...
متن کاملMycophenolate mofetil for myasthenia gravis: an open-label pilot study.
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 w...
متن کاملEpstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications.
Unlike primary central nervous system lymphomas (PCNSLs) in patients with AIDS or organ transplants, PCNSLs in the elderly are usually not considered to be mediated by Epstein Barr virus (EBV); hence, diagnostic studies for EBV are not routinely performed. We encountered 4 patients, 65 years or older, who developed EBV-associated PCNSLs and who had been treated with a variety of immunosuppressi...
متن کاملTreatment of myasthenia gravis.
Myasthenia gravis is a prototypic antibody-mediated neurological autoimmune disorder. Its pathogenesis is much better understood than that of multiple sclerosis or immune neuropathies. Currently two targets in the endplate membrane are considered as autoantigens, the acetylcholine receptor (in up to 90%) and the muscle-specific kinase (MuSK, in about 5%). Fortunately, substantial therapeutic pr...
متن کاملBortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
Background Myasthenia gravis (MG) is an autoimmune disease caused by antibodies to different antigens of the neuromuscular junction, in particular to acetylcholine receptor (AChR) and muscle tyrosine kinase (MuSK).1 Standard therapies comprise pyridostigmine, glucocorticosteroids, azathioprine or alternatively mycophenolate mofetil, cyclosporine A and tacrolimus. In severe MG, escalating immuno...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of neuroimmunology
دوره 201-202 شماره
صفحات -
تاریخ انتشار 2008